Analysis of tear film in cystinosis patients treated with topical viscous cysteamine hydrochloride (Cystadrops
corneal crystal
ocular cystinosis
tear osmolarity
Journal
European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
8
2
2022
medline:
4
10
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
The aim of this study was to evaluate Ten eyes of five patients with nephropathic cystinosis aged from 10 to 35 years were included in this study. The patients were under treatment with viscous cysteamine hydrochloride formulation containing 3.8 mg/mL cysteamine (vCH 0.55%, equivalent to 0.55% CH; Cystadrops Mean tear osmolarity was 294.8 mOsms/L (±10.4), with a mean absolute difference of 1.85 mOsms/L (±2.13) between the eyes. There was no statistically significant difference between the osmolarity readings of cystinosis and the control group (294.8 ± 10.4 vs 299.4 ± 6.2mOsm/L, respectively; p = 0.39). The mean TBUT was 10.2 ± 0.83 s in the study group versus 10 ± 0.7 s in controls (p = 0.62). The mean Schirmer test score was 9.2 ± 0.83 mm in the patients versus 10.2 ± 0.83 mm in the controls (p = 0.14). The TearLab
Identifiants
pubmed: 35125035
doi: 10.1177/11206721221078649
pmc: PMC9527349
doi:
Substances chimiques
Cysteamine
5UX2SD1KE2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3358-3362Références
Cornea. 2002 Mar;21(2):173-6
pubmed: 11862089
Ocul Surf. 2009 Oct;7(4):186-98
pubmed: 19948102
Science. 1982 Sep 24;217(4566):1263-5
pubmed: 7112129
Cornea. 2011 Dec;30(12):1289-92
pubmed: 22001814
Ther Adv Ophthalmol. 2018 Aug 21;10:2515841418794886
pubmed: 30151502
Arch Ophthalmol. 1986 May;104(5):706-11
pubmed: 3518682
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6125-30
pubmed: 20631232
Mol Genet Metab. 2000 Sep-Oct;71(1-2):100-20
pubmed: 11001803
N Engl J Med. 1987 Mar 26;316(13):775-9
pubmed: 3821824
Cornea. 2012 Sep;31(9):1000-8
pubmed: 22475641
Clin Exp Ophthalmol. 2008 Nov;36(8):778-81
pubmed: 19128385
Prog Retin Eye Res. 2010 Jan;29(1):59-78
pubmed: 19944776
Clin Ophthalmol. 2018 Jan 24;12:227-236
pubmed: 29416314
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2275-2283
pubmed: 28426870
Mol Genet Metab. 2014 Mar;111(3):314-320
pubmed: 24440466
J Pediatr. 2017 Apr;183S:S19-S21
pubmed: 28343471
Am J Ophthalmol. 2011 May;151(5):792-798.e1
pubmed: 21310379
Pain. 2014 Aug;155(8):1481-1491
pubmed: 24785271
Ocul Surf. 2007 Apr;5(2):75-92
pubmed: 17508116
Clin Exp Optom. 2012 Jan;95(1):3-11
pubmed: 22022802
Optom Vis Sci. 2009 Nov;86(11):1235-40
pubmed: 19770810
Eur J Pharm Biopharm. 2008 Sep;70(1):260-9
pubmed: 18590953
Cornea. 2010 Sep;29(9):1036-41
pubmed: 20577088
Arch Ophthalmol. 1990 May;108(5):689-93
pubmed: 2185723
Curr Eye Res. 2010 Jul;35(7):553-64
pubmed: 20597641
Ocul Surf. 2013 Oct;11(4):246-58
pubmed: 24112228